title: Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia.
abstract: Although haematopoietic cell transplantation (HCT) is curative for sickle cell anaemia (SCA), concerns about its short- and long-term toxicities limit its application. A potential toxicity is an adverse effect on growth. To identify an HCT growth effect, serial height and weight measurements from 53 children and adolescents with SCA after receiving a transplant were compared to historical controls. Hierarchical Linear Models for longitudinal data were used for analysis. In general growth was not impaired by HCT for SCA in young children; however, diminished growth may occur if HCT is carried out near or during the adolescent growth spurt.
authors.affiliation: Blood and Marrow Transplantation Program, Children's Hospital and Research Center, Oakland, CA 94609, USA.
authors.forename: B
authors.initials: B
authors.lastname: Eggleston
authors.forename: M
authors.initials: M
authors.lastname: Patience
authors.forename: S
authors.initials: S
authors.lastname: Edwards
authors.forename: T
authors.initials: T
authors.lastname: Adamkiewicz
authors.forename: G R
authors.initials: GR
authors.lastname: Buchanan
authors.forename: S C
authors.initials: SC
authors.lastname: Davies
authors.forename: R
authors.initials: R
authors.lastname: Dickerhoff
authors.forename: S
authors.initials: S
authors.lastname: Donfield
authors.forename: S A
authors.initials: SA
authors.lastname: Feig
authors.forename: R H
authors.initials: RH
authors.lastname: Giller
authors.forename: A
authors.initials: A
authors.lastname: Haight
authors.forename: J
authors.initials: J
authors.lastname: Horan
authors.forename: L L
authors.initials: LL
authors.lastname: Hsu
authors.forename: N
authors.initials: N
authors.lastname: Kamani
authors.forename: P
authors.initials: P
authors.lastname: Lane
authors.forename: J E
authors.initials: JE
authors.lastname: Levine
authors.forename: D
authors.initials: D
authors.lastname: Margolis
authors.forename: T B
authors.initials: TB
authors.lastname: Moore
authors.forename: K
authors.initials: K
authors.lastname: Ohene-Frempong
authors.forename: R
authors.initials: R
authors.lastname: Redding-Lallinger
authors.forename: I A G
authors.initials: IA
authors.lastname: Roberts
authors.forename: Z R
authors.initials: ZR
authors.lastname: Rogers
authors.forename: J E
authors.initials: JE
authors.lastname: Sanders
authors.forename: J P
authors.initials: JP
authors.lastname: Scott
authors.forename: B
authors.initials: B
authors.lastname: Sleight
authors.forename: A A
authors.initials: AA
authors.lastname: Thompson
authors.forename: K M
authors.initials: KM
authors.lastname: Sullivan
authors.forename: M C
authors.initials: MC
authors.lastname: Walters
mesh_terms: D000367:Age Factors; D000375:Aging / Q000502:physiology; D000755:Anemia, Sickle Cell / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D000986:Antisickling Agents / Q000627:therapeutic use; D001827:Body Height; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006128:Growth; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008297:Male; D015430:Weight Gain
chemical_list: D000986:Antisickling Agents; D006918:Hydroxyurea